potential subjects meeting any of the following criteria will be excluded from enrollment: 1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; 3. subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; 4. subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; 5. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); 6. subject with active hepatitis b and hepatitis c; 7. subjects who are participating in other clinical trials; 8. subjects that have had any covid19 vaccination; 9. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; 10. inability to provide informed consent or to comply with study requirements; and 11. subjects who are pregnant or breast-feeding.

potential subjects meeting any of the following criteria will be excluded from enrollment: 1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; 3. subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; 4. subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; 5. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); 6. subject with active hepatitis b and hepatitis c; 7. subjects who are participating in other clinical trials; 8. subjects that have had any covid19 vaccination; 9. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; 10. inability to provide informed consent or to comply with study requirements; and 11. subjects who are pregnant or breast-feeding.

potential subjects meeting any of the following criteria will be excluded from enrollment: subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); subject with active hepatitis b and hepatitis c; subjects who are participating in other clinical trials; subjects that have had any covid19 vaccination; subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; inability to provide informed consent or to comply with study requirements; and subjects who are pregnant or breast-feeding.

potential subjects meeting any of the following criteria will be excluded from enrollment: subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); subject with active hepatitis b and hepatitis c; subjects who are participating in other clinical trials; subjects that have had any covid19 vaccination; subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; inability to provide informed consent or to comply with study requirements; and subjects who are pregnant or breast-feeding.

potential subjects meeting any of the following criteria will be excluded from enrollment: 1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; 3. subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; 4. subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; 5. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); 6. subject with active hepatitis b and hepatitis c; 7. subjects who are participating in other clinical trials; 8. subjects that have had any covid19 vaccination; 9. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; 10. inability to provide informed consent or to comply with study requirements; and 11. subjects who are pregnant or breast-feeding.

potential subjects meeting any of the following criteria will be excluded from enrollment: 1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; 3. subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; 4. subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; 5. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); 6. subject with active hepatitis b and hepatitis c; 7. subjects who are participating in other clinical trials; 8. subjects that have had any covid19 vaccination; 9. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; 10. inability to provide informed consent or to comply with study requirements; and 11. subjects who are pregnant or breast-feeding.

1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; 3. subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; 4. subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; 5. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); 6. subject with active hepatitis b and hepatitis c; 7. subjects who are participating in other clinical trials; 8. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; 9. inability to provide informed consent or to comply with study requirements; and 10. subjects who are pregnant or breast-feeding.

1. subjects showing signs of acute respiratory distress syndrome (ards) or respiratory failure necessitating mechanical ventilation at the time of screening; 2. subjects who have history of receiving nac, prothione™ capsules or gsh supplements in the past 30 days before the screening visit; 3. subjects who have history of receiving corticosteroids (topical corticosteroid is excluded) in the past 30 days; 4. subjects who are currently receiving chemotherapy or immunotherapy for the treatment of cancer; 5. any uncontrolled active systemic infection requiring admission to an intensive care unit (icu); 6. subject with active hepatitis b and hepatitis c; 7. subjects who are participating in other clinical trials; 8. subjects who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to prothione™ are not eligible; 9. inability to provide informed consent or to comply with study requirements; and 10. subjects who are pregnant or breast-feeding.